Treatment Recommendations for Small Renal Masses

Primary Treatment Options

The European Association of Urology recommends partial nephrectomy as the preferred treatment for patients with T1a tumors (<4 cm), including a 1.8 cm lesion, as it provides equivalent oncological outcomes to radical nephrectomy while preserving renal function and reducing cardiovascular morbidity 1, 2
The National Comprehensive Cancer Network recommends that partial nephrectomy should be offered to all patients with T1a tumors (<4 cm), including this 1.8 cm lesion 1, 2
Both laparoscopic and open approaches provide comparable outcomes when performed by skilled surgeons, with the goal of optimal tumor control while minimizing ischemia time to <30 minutes 2

Active surveillance is appropriate for patients with significant comorbidities or decreased life expectancy, and short- and intermediate-term data support initial monitoring with delayed intervention if progression occurs 2
Thermal ablation (radiofrequency, microwave, or cryoablation) may be considered for frail patients with high surgical risk or compromised renal function, but carries increased local recurrence risk compared to surgery 1, 2, 3

The European Urology guidelines recommend calculating creatinine clearance using Cockcroft-Gault or MDRD equations rather than relying on serum creatinine alone, as serum creatinine underestimates renal dysfunction in elderly patients 3
A percutaneous renal mass biopsy must be performed before ablation to confirm malignancy, and core biopsy is recommended before ablative therapies but not required before surgical excision 1, 3

The European Association of Urology and the National Comprehensive Cancer Network recommend not performing radical nephrectomy when partial nephrectomy is technically feasible, as it increases the risk of chronic kidney disease and associated cardiovascular morbidity and mortality 1, 2

Regular follow-up imaging with CT of chest, abdomen, and pelvis should be implemented to detect recurrence early, and intensify follow-up if positive surgical margins are found, especially with upstaged pT3a disease 1, 3, 4

The National Comprehensive Cancer Network recommends that treatment decisions must account for competing health risks and life expectancy, and quality of life considerations are paramount when survival benefit is uncertain 2, 3, 4
Elderly patients have increased vulnerability to treatment-related toxicity, and the decision between surgery, active surveillance, and ablation should weigh perioperative complication risks against the risk of developing or worsening chronic kidney disease 1, 2, 3, 4